Neuro-Oncology and Stem Cell Research Laboratory (NSCL), Center for Neuroscience Research (CNR), CHOC Children's Research Institute (CCRI), Children's Hospital of Orange County (CHOC), 1201 West La Veta Ave., Orange, CA 92868-3874, USA.
Department of Neurology, University of California-Irvine School of Medicine, 200 S Manchester Ave Ste 206, Orange, CA 92868, USA.
Biomolecules. 2020 May 1;10(5):704. doi: 10.3390/biom10050704.
Common clinical options, currently, for necessary splenectomy are vaccinations and antibiotic prophylaxis. However, despite these two adjuncts, there still occur numerous cases of overwhelming post-splenectomy infection. To examine whether reperfusion of critical splenic lymphocytes could boost immune response, we harvested splenic lymphocytes, reperfused the autologous lymphocytes, and then administered a pneumococcal vaccine (PNEUMOVAX23, i.e., PPSV23) in splenectomized mice. We found that splenectomy impaired the immune response in the splenectomized group compared to the non-splenectomized group; the splenectomized group with lymphocyte reinfusion had a higher response to polysaccharide vaccination based on antibody titer than the splenectomized group without lymphocyte reinfusion. The sham group with the native spleen had the most elevated antibody titer against the PPSV23 polysaccharide antigen. This may be additive, resulting from contributions of the splenic structure, along with the phagocytic function of the spleen and its constituent cells affecting the antibody response. Reinfusion of splenic lymphocytes may enhance immunity without the complications associated with splenic fragment autotransplantation, which never gained acceptance. This technique is safe and simple since the splenic lymphocytes are autologous and, therefore, not self-reactive, and very similar to autologous blood transfusion. This concept may be beneficial in cases of unavoidable splenectomy, especially in pediatric cases.
目前，对于必要的脾切除术，常见的临床选择是接种疫苗和抗生素预防。然而，尽管有这两种辅助措施，仍然会发生许多感染性脾切除术后感染的情况。为了研究脾内关键淋巴细胞再灌注是否可以增强免疫反应，我们采集了脾淋巴细胞，再灌注了自体淋巴细胞，然后在脾切除的小鼠中给予肺炎球菌疫苗（PNEUMOVAX23，即 PPSV23）。我们发现与非脾切除组相比，脾切除组的免疫反应受损；与未进行淋巴细胞再灌注的脾切除组相比，进行淋巴细胞再灌注的脾切除组的多糖疫苗接种反应更高，抗体滴度更高。保留有天然脾脏的假手术组对 PPSV23 多糖抗原的抗体滴度最高。这可能是附加的，因为脾的结构、脾及其组成细胞的吞噬功能会影响抗体反应。脾内淋巴细胞再灌注可能会增强免疫力，而不会出现脾段自体移植相关的并发症，后者从未被接受。由于脾淋巴细胞是自体的，因此不会自我反应，与自体输血非常相似，因此该技术安全且简单。对于不可避免的脾切除术，尤其是儿科病例，这一概念可能是有益的。
